166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study
| Autor: | Schmid, P., Jung, K.H., Wysocki, P.J., Jassem, J., Ma, C.X., Fernandes, R., Huisden, R., Stewart, R., Vukovic, P., Tablante Nunes, A., Nowecki, Z. |
|---|---|
| Zdroj: | In Annals of Oncology May 2022 33 Supplement 3:S199-S199 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|